This is a working overview of adipose tissue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== Discrimination against ethnic minorities == Non-Arab ethnic groups in Syrian society were heavily marginalized in Ba'athist Syria. Ethnic minority groups in Syria like the Kurds, Turkmen, Circassians, Chechens, etc. were systematically persecuted and racially discriminated under Ba'athist state practices. Ba'ath party's front organizations such as the "Ba'ath Vanguard" and "Shabibat al-Thawra" imposed a racially discriminatory Arab nationalist ideology through Syrian state educational institutions. Languages other than Arabic were not recognized in the Ba'athist constitutions. The 2012 constitution pushed by Bashar al-Assad, which was widely criticized by Syrian opposition and civil society activists, further entrenched the discriminatory policies of the Ba'athist system. Syrian Kurds, in particular, were heavily brutalized and systemically targeted by the state apparatus. During the 1970s, the Hafez al-Assad launched the Ba'ath party's ethnic cleansing policy of Arab Belt project along north-eastern Syria, seizing lands owned by Kurdish families and forcibly displacing them. Hundreds of thousands of Kurds were stripped of citizenship, and several Kurdish localities were Arabized. Assad regime also banned the speaking of Kurdish language in workplaces and public events, and launched crackdowns against those who taught the Kurdish language privately. Kurdish tutors were forcibly disappered or subjected to prolonged imprisonments under charges of fomenting "separatism", treason, and undermining the stability of the Ba'athist state.
Overall, the available evidence suggests that laser-based techniques are a minimally invasive treatment option for pilonidal disease with favorable short-term outcomes, while long-term outcomes remain to be further evaluated, necessitating long-term studies to assess its effectiveness as a first-line treatment.
SASP induces an unfolded protein response in the endoplasmic reticulum because of an accumulation of unfolded proteins, resulting in proteotoxic impairment of cell function. SASP cytokines can result in an inflamed stem cell niche, leading to stem cell exhaustion and impaired stem cell function. The pro-inflammatory environment generated by SASP factors accelerates the breakdown of extracellular matrix thereby worsening intervertebral disc degeneration (IVDD). AMPK/p53 senescence produces a completely different SASP than IL-1 (p16INK4a) senescence, which is primarily responsible for IVDD. In IVDD, SASP is secreted by nucleus pulposus and annulus fibrosus cells, resulting in extracellular matrix degradation and extracellular inflammation. Senomorphics, but not senolytics have been found to alleviate symptoms without eliminating senescent cells. SASP can either promote or inhibit cancer, depending on the SASP composition, notably including p53 status. Despite the fact that cellular senescence likely evolved as a means of protecting against cancer early in life, SASP promotes the development of late-life cancers. Cancer invasiveness is promoted primarily through the actions of the SASP factors metalloproteinase, chemokine, interleukin 6 (IL-6), and interleukin 8 (IL-8). In fact, SASP from senescent cells is associated with many aging-associated diseases, including not only cancer, but atherosclerosis and osteoarthritis. For this reason, senolytic therapy has been proposed as a generalized treatment for these and many other diseases.
Prime Minister Rishi Sunak meets with US president Joe Biden at the Grand Central Hotel in Belfast. Biden makes a keynote speech at the Ulster University during which he urges Northern Ireland's politicians to restore the power-sharing government. A 74-year-old man is extradited from Pakistan and charged with murdering police officer Sharon Beshenivsky in November 2005. Tesco reduces the price of a four pint bottle of milk from £1.65 to £1.55 following a cut in wholesale prices. Coronation of Charles III and Camilla: Buckingham Palace confirms that the Duke of Sussex will attend the coronation, but that the Duchess will remain in the United States with their children. 13 April Data published by the Office for National Statistics shows a 0% growth in the UK economy during February as growth in the construction industry was offset by industrial action. Publication of the Deciphering Developmental Disorders study, a study involving children with development disorders, which has identified 60 new health conditions. Sainsbury's follows Tesco in cutting the price of milk. A report published by Diabetes UK indicates the UK is heading for what the charity describes as a "rapidly escalating diabetes crisis", with 4.3 million people experiencing a form of diabetes, a further 850,000 estimated to be living with the disease but unaware of it, and another 2.4 million people at risk of developing the condition. Cases of diabetes are more prevalent in less affluent areas of the country. 14 April Ford receives government approval for its "BlueCruise" Level 2 autonomous driving technology.
Sources: en.wikipedia.org
In general, the A (aminoacyl) site contains an aminoacyl-tRNA (a tRNA esterified to an amino acid on the 3' end). The P (peptidyl) site contains a tRNA esterified to the nascent peptide. The free amino (NH2) group of the A site tRNA attacks the ester linkage of P site tRNA, causing transfer of the nascent peptide to the amino acid in the A site. This reaction is takes place in the peptidyl transferase center The E (exit) site contains a tRNA that has been discharged, with a free 3' end (with no amino acid or nascent peptide). A single mRNA can be translated simultaneously by multiple ribosomes. This is called a polysome. In prokaryotes, much work has been done to further identify the importance of rRNA in translation of mRNA. For example, it has been found that the A site consists primarily of 16S rRNA. Apart from various protein elements that interact with tRNA at this site, it is hypothesized that if these proteins were removed without altering ribosomal structure, the site would continue to function normally. In the P site, through the observation of crystal structures it has been shown the 3' end of 16s rRNA can fold into the site as if a molecule of mRNA. This results in intermolecular interactions that stabilize the subunits. Similarly, like the A site, the P site primarily contains rRNA with few proteins. The peptidyl transferase center, for example, is formed by nucleotides from the 23S rRNA subunit. In fact, studies have shown that the peptidyl transferase center contains no proteins, and is entirely initiated by the presence of rRNA.
Compounds and their metabolites need to be removed from the body via excretion, usually through the kidneys (urine) or in the feces. Unless excretion is complete, accumulation of foreign substances can adversely affect normal metabolism. There are three main sites where drug excretion occurs. The kidney is the most important site and it is where products are excreted through urine. Biliary excretion or fecal excretion is the process that initiates in the liver and passes through to the gut until the products are finally excreted along with waste products or feces. The last main method of excretion is through the lungs (e.g. anesthetic gases). Excretion of drugs by the kidney involves 3 main mechanisms:
=== Pharmacokinetics === Given by subcutaneous injection, the elimination half-life of luvesilocin is 0.43 to 0.64 hours and of 4-HO-DiPT is 2.7 to 4.1 hours. The mean duration with this route at the employed dose was 3.6 hours.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.